In a first-in-human Phase I trial (NCT04665206) for advanced solid tumors enriched with NF2-mutant mesothelioma patients, VT3989 has demonstrated a tolerable safety profile and preliminary antitumor activity. The gene discussed is NF2; the disease is mesothelioma.